{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,31]],"date-time":"2022-03-31T14:15:09Z","timestamp":1648736109246},"reference-count":32,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2014,3,1]],"date-time":"2014-03-01T00:00:00Z","timestamp":1393632000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Advances in Chronic Kidney Disease"],"published-print":{"date-parts":[[2014,3]]},"DOI":"10.1053\/j.ackd.2014.01.012","type":"journal-article","created":{"date-parts":[[2014,3,4]],"date-time":"2014-03-04T04:01:59Z","timestamp":1393905719000},"page":"115-118","source":"Crossref","is-referenced-by-count":0,"title":["Treatment of Nephrotic Syndrome: Retrospection"],"prefix":"10.1053","volume":"21","author":[{"given":"Jerry","family":"Yee","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1053\/j.ackd.2014.01.012_bib1","unstructured":"Definition from the UK National Institute for Clinical Effectiveness (NICE). 2004. Citizen Council Report on Ultra-Orphan Drugs. Available at: http:\/\/tinyurl.com\/b3qurp3 and as defined in the following documents: Wales Medicines Strategy Group (AWMSG); Recommendations for a Belgian Plan for Rare Diseases; the EMINET Report commissioned by the European Commission's Directorate General Enterprise and Industry, the European Union Committee of Experts on Rare Diseases' (EUCERD). Accessed January 5,\u00a02014."},{"issue":"9","key":"10.1053\/j.ackd.2014.01.012_bib2","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1681\/ASN.2007030356","article-title":"for the Dense Deposit Disease Focus Group. New approaches to the treatment of dense deposit disease","volume":"18","author":"Smith","year":"2007","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.012_bib3","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1038\/kisup.2012.9","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int Suppl"},{"issue":"3","key":"10.1053\/j.ackd.2014.01.012_bib4","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2215\/CJN.04291007","article-title":"Endothelial dysfunction in patients with chronic kidney disease results from advanced glycation end products (AGE)-mediated inhibition of endothelial nitric oxide synthase through rage activation","volume":"3","author":"Linden","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"10.1053\/j.ackd.2014.01.012_bib5","first-page":"357","article-title":"Glomerular basement membrane discontinuities. Scanning electron microscopic study of acellular glomeruli","volume":"119","author":"Bonsib","year":"1985","journal-title":"Am J Pathol"},{"key":"10.1053\/j.ackd.2014.01.012_bib6","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nm.1857","article-title":"The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A","volume":"14","author":"Faul","year":"2008","journal-title":"Nat Med"},{"issue":"1","key":"10.1053\/j.ackd.2014.01.012_bib7","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1038\/nrneph.2011.151","article-title":"The podocyte cytoskeleton\u2014key to a functioning glomerulus in health and disease","volume":"8","author":"Welsh","year":"2012","journal-title":"Nat Rev Nephrol"},{"issue":"6","key":"10.1053\/j.ackd.2014.01.012_bib8","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1038\/ki.1987.151","article-title":"Albumin synthesis, albuminuria and hyperlipemia in nephrotic patients","volume":"31","author":"Kaysen","year":"1987","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2014.01.012_bib9","doi-asserted-by":"crossref","first-page":"1964","DOI":"10.1046\/j.1523-1755.2003.00941.x","article-title":"Nephrology forum: molecular mechanisms of lipid disorders in nephrotic syndrome","volume":"63","author":"Vaziri","year":"2003","journal-title":"Kidney Int"},{"issue":"13","key":"10.1053\/j.ackd.2014.01.012_bib10","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJM199403313301301","article-title":"The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease","volume":"330","author":"Klahr","year":"1994","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1053\/j.ackd.2014.01.012_bib11","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1542\/peds.5.3.486","article-title":"Nephrotic syndrome. I: natural history of the disease","volume":"5","author":"Barness","year":"1950","journal-title":"Pediatrics"},{"issue":"3","key":"10.1053\/j.ackd.2014.01.012_bib12","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/S0272-6386(12)80899-7","article-title":"Risk factors for infection and immunoglobulin replacement therapy in adult nephrotic syndrome","volume":"24","author":"Ogi","year":"1994","journal-title":"Am J Kidney Dis"},{"key":"10.1053\/j.ackd.2014.01.012_bib13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/kisup.2013.27","volume":"3","author":"Kroger","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1053\/j.ackd.2014.01.012_bib14","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/kisup.2013.27","article-title":"Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease","volume":"3","year":"2013","journal-title":"Kidney Inter Suppl"},{"issue":"2","key":"10.1053\/j.ackd.2014.01.012_bib15","first-page":"CD007784","article-title":"HMGCoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis","author":"Navaneethan","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1053\/j.ackd.2014.01.012_bib16","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1111\/j.1523-1755.2005.09911.x","article-title":"The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease","volume":"99","author":"Remuzzi","year":"2005","journal-title":"Kidney Int Suppl"},{"issue":"20","key":"10.1053\/j.ackd.2014.01.012_bib17","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"Fried","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1053\/j.ackd.2014.01.012_bib18","doi-asserted-by":"crossref","first-page":"2641","DOI":"10.1681\/ASN.2009070737","article-title":"Addition of angiotensin receptor blockade or mineralocorticoid antagonism to maximal angiotensin-converting enzyme inhibition in diabetic nephropathy","volume":"20","author":"Mehdi","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"5","key":"10.1053\/j.ackd.2014.01.012_bib19","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1093\/ndt\/gfh127","article-title":"Pentoxifylline suppresses renal tumour necrosis factor-alpha and ameliorates experimental crescentic glomerulonephritis in rats","volume":"19","author":"Chen","year":"2004","journal-title":"Nephrol Dial Transplant"},{"issue":"6","key":"10.1053\/j.ackd.2014.01.012_bib20","first-page":"790","article-title":"The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial","volume":"32","author":"Ghorbani","year":"2012","journal-title":"Nefrologia"},{"issue":"1","key":"10.1053\/j.ackd.2014.01.012_bib21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1681\/ASN.2011040430","article-title":"Sodium intake, ACE inhibition, and progression to ESRD","volume":"23","author":"Vegter","year":"2012","journal-title":"J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.012_bib22","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/ndt\/13.7.1682","article-title":"The blunting of the antiproteinuric efficacy of ACE inhibition by high sodium intake can be restored by hydrochlorothiazide","volume":"13","author":"Buter","year":"1998","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"10.1053\/j.ackd.2014.01.012_bib23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1681\/ASN.2008040364","article-title":"Plasmin in nephrotic urine activates the epithelial sodium channel","volume":"20","author":"Svenningsen","year":"2009","journal-title":"J Am Soc Nephrol"},{"issue":"21","key":"10.1053\/j.ackd.2014.01.012_bib24","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa1306357","article-title":"Vitamin D-binding protein and vitamin D status of black Americans and white Americans","volume":"369","author":"Powe","year":"2013","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1053\/j.ackd.2014.01.012_bib25","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1681\/ASN.2006111300","article-title":"Prophylactic anticoagulation in nephrotic syndrome: a clinical conundrum","volume":"18","author":"Glassock","year":"2007","journal-title":"J Am Soc Nephrol"},{"issue":"1","key":"10.1053\/j.ackd.2014.01.012_bib26","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2215\/CJN.04250511","article-title":"Venous thromboembolism in patients with membranous nephropathy","volume":"7","author":"Lionaki","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.012_bib27","doi-asserted-by":"crossref","DOI":"10.2215\/CJN.07190713","article-title":"Retrospective analysis of a novel regimen for the prevention of venous thromboembolism in nephrotic syndrome","author":"Medjeral-Thomas","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1053\/j.ackd.2014.01.012_bib28","doi-asserted-by":"crossref","DOI":"10.1038\/ki.2013.476","article-title":"Personalized prophylactic anticoagulation decision analysis in patients with membranous nephropathy","author":"Lee","year":"2013","journal-title":"Kidney Int"},{"issue":"2","key":"10.1053\/j.ackd.2014.01.012_bib29","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ki.2011.44","article-title":"Warfarin-related nephropathy occurs in patients with and without chronic kidney disease and is associated with an increased mortality rate","volume":"80","author":"Brodsky","year":"2011","journal-title":"Kidney Int"},{"key":"10.1053\/j.ackd.2014.01.012_bib30","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gft380","article-title":"Warfarin-related nephropathy is the tip of the iceberg: direct thrombin inhibitor dabigatran induces glomerular hemorrhage with acute kidney injury in rats","author":"Ryan","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"10.1053\/j.ackd.2014.01.012_bib31","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1093\/ckj\/sft076","article-title":"Warfarin-related nephropathy in a patient with mild IgA nephropathyon dabigatran and aspirin","volume":"6","author":"Moekel","year":"2013","journal-title":"Clin Kidney J"},{"issue":"3","key":"10.1053\/j.ackd.2014.01.012_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0272-6386(87)80170-1","article-title":"The nephrotic syndrome and its complications","volume":"10","author":"Cameron","year":"1987","journal-title":"Am J Kidney Dis"}],"container-title":["Advances in Chronic Kidney Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559514000159?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1548559514000159?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,3,28]],"date-time":"2022-03-28T10:51:45Z","timestamp":1648464705000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1548559514000159"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["S1548559514000159"],"URL":"https:\/\/doi.org\/10.1053\/j.ackd.2014.01.012","relation":{},"ISSN":["1548-5595"],"issn-type":[{"value":"1548-5595","type":"print"}],"subject":[],"published":{"date-parts":[[2014,3]]}}}